ProCE Banner Activity

CE / CME

Medical Minute 3: Innovations in Alzheimer’s Disease: Amyloid-Targeted Therapies

Video

Amyloid-targeted therapies have recently entered the treatment paradigm for early Alzheimer’s disease—an exciting development as these agents are disease-modifying therapies, rather than symptom-targeting therapies, for a progressive neurodegenerative disease. In this Medical Minute, healthcare professionals will learn valuable information about these agents and their use in clinical practice. 

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: October 20, 2023

Expiration: October 19, 2024

Share

Faculty

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Eisai.

Eisai

Target Audience

This program is intended for healthcare professionals caring for patients with AD including neurologists, psychiatrists, primary care physicians, nurse practitioners, physician associates, pharmacisis, and those specializing in geriatrics, AD, and/or dementia.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Alzheimer's

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Assess the evidence for efficacy and safety profiles of newer agents used in the treatment of AD

  • Construct an individualized care plan for patients with AD

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Susan Scanland, MSN, CRNP, GNP-BC, CDP: consultant/advisor/speaker: Acadia, BioXcel, Eisai, Otsuka/Lundbeck, Teva.

The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose, except Michael Asbach, DMSc, PA-C, Psych-CAQ as noted below:

Michael Asbach, DMSc, PA-C, Psych-CAQ: consultant/advisor/speaker: AbbVie, Avanir, Biogen, Janssen, Karuna, Neurocrine, Otsuka.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 20, 2023, through October 19, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of 65 or better and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Logo, company nameDescription automatically generatedIn support of improving patient care, Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours.

Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until October 19, 2024. PAs should only claim credit commensurate with the extent of their participation. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008176-0000-23-259-H01-P 
Type of Activity: Knowledge  

Upon successfully completing the post-test with a score of 65 and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.